Effectiveness of polydeoxyribonucleotide injection versus normal saline injection for treatment of chronic plantar fasciitis: a prospective randomised clinical trial

Kim, Jae Kwang; Chung, Jae Yoon

doi:10.1007/s00264-015-2772-0

Cited by 47 publications

(43 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, PDRN has been proven effective in the treatment (intradermal administration) of chronic plantar fasciitis (Kim and Chung, 2015) and in the therapeutic management (topical application) of female pattern hair loss (Lee et al, 2015). …”

Section: Introductionmentioning

confidence: 99%

Pharmacological Activity and Clinical Use of PDRN

et al. 2017

View full text Add to dashboard Cite

PDRN is a proprietary and registered drug that possesses several activities: tissue repairing, anti-ischemic, and anti-inflammatory. These therapeutic properties suggest its use in regenerative medicine and in diabetic foot ulcers. PDRN holds a mixture of deoxyribonucleotides with molecular weights ranging between 50 and 1,500 KDa, it is derived from a controlled purification and sterilization process of Oncorhynchus mykiss (Salmon Trout) or Oncorhynchus keta (Chum Salmon) sperm DNA. The procedure guarantees the absence of active protein and peptides that may cause immune reactions. In vitro and in vivo experiments have suggested that PDRN most relevant mechanism of action is the engagement of adenosine A2A receptors. Besides engaging the A2A receptor, PDRN offers nucleosides and nucleotides for the so called “salvage pathway.” The binding to adenosine A2A receptors is a unique property of PDRN and seems to be linked to DNA origin, molecular weight and manufacturing process. In this context, PDRN represents a new advancement in the pharmacotherapy. In fact adenosine and dipyridamole are non-selective activators of adenosine receptors and they may cause unwanted side effects; while regadenoson, the only other A2A receptor agonist available, has been approved by the FDA as a pharmacological stress agent in myocardial perfusion imaging. Finally, defibrotide, another drug composed by a mixture of oligonucleotides, has different molecular weight, a DNA of different origin and does not share the same wound healing stimulating effects of PDRN. The present review analyses the more relevant experimental and clinical evidences carried out to characterize PDRN therapeutic effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacological Activity and Clinical Use of PDRN

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In line with the current form of the Cochrane risk of bias tool, we did not include funding in the quality assessment of the trials. Eight RCTs were conducted in Asia,47 48 54 56–60 five in Europe,51 55 61–63 five in America,49 52 53 64 65 two in Africa66 67 and two in Australia 46 50. The registration protocols were available for six studies in this review 46 50–52 55 62.…”

Section: Resultsmentioning

confidence: 99%

Injection therapies for plantar fasciopathy (‘plantar fasciitis’): a systematic review and network meta-analysis of 22 randomised controlled trials

2016

View full text Add to dashboard Cite

show abstract

“…Studies on musculoskeletal tissue regeneration were conducted on: (1) bone tissue, one in vitro on osteoblasts (OBs) (Guizzardi et al, ), two in vivo in rat bone defects and subcutaneous pockets (Guizzardi et al, ; Kim et al, ) and one in patients affected by ischiofemoral impingement syndrome (IFI) (Kim et al, ); (2) cartilage tissue, one in vitro on cartilage explants (Gennero et al, ), two in patients affected by knee OA (Vanelli et al, ; Giarratana et al, ) and one both in vitro, on chondrocytes from patients affected by rheumatoid arthritis (RA), and in vivo in mice affected by arthritis (CIA) (Bitto et al, ); (3) tendon tissue in patients affected by plantar fasciitis (Kim and Chung, ).…”

Section: Resultsmentioning

confidence: 99%

“…The only study about tendon regeneration was performed in patients affected by plantar fasciitis. Three injections of 0.75 ml of PDRNs reduced pain and increased physical function, in comparison to saline solution injection, 12 weeks after the last injection (Kim and Chung, ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Polydeoxyribonucleotides (PDRNs) From Skin to Musculoskeletal Tissue Regeneration via Adenosine A_2A Receptor Involvement

Veronesi

Carubbi

Martini

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

Polydeoxyribonucleotides (PDRNs) are low molecular weight DNA molecules of natural origin that stimulate cell migration and growth, extracellular matrix (ECM) protein production, and reduce inflammation. Most preclinical and clinical studies on tissue regeneration with PDRNs focused on skin, and only few are about musculoskeletal tissues. Starting from an overview on skin regeneration studies, through the analysis of in vitro, in vivo, and clinical studies (1990-2016), the present review aimed at defining the effects of PDRN and their mechanisms of action in the regeneration of musculoskeletal tissues. This would also help future researches in this area. A total of 29 studies were found by PubMed and www.webofknowledge.com searches: 20 were on skin (six in vitro, six in vivo, one vitro/vivo, seven clinical studies), while the other nine regarded bone (one in vitro, two in vivo, one clinical studies), cartilage (one in vitro, one vitro/vivo, two clinical studies), or tendon (one clinical study) tissues regeneration. PDRNs improved cell growth, tissue repair, ECM proteins, physical activity, and reduced pain and inflammation, through the activation of adenosine A receptor. PDRNs are currently used for bone, cartilage, and tendon diseases, with a great variability regarding the PDRN dosage to be used in clinical practice, while the dosage for skin regeneration is well established. PDRNs are usually administered from a minimum of three to a maximum of five times and they act trough the activation of A receptor. Further studies are advisable to confirm the effectiveness of PDRNs and to standardize the PDRN dose. J. Cell. Physiol. 232: 2299-2307, 2017. © 2016 Wiley Periodicals, Inc.

show abstract

Effectiveness of polydeoxyribonucleotide injection versus normal saline injection for treatment of chronic plantar fasciitis: a prospective randomised clinical trial

Abstract: PDRN injection is an effective and safe treatment option and may be considered for plantar fasciitis.

Cited by 47 publications

References 28 publications

Pharmacological Activity and Clinical Use of PDRN

Pharmacological Activity and Clinical Use of PDRN

Injection therapies for plantar fasciopathy (‘plantar fasciitis’): a systematic review and network meta-analysis of 22 randomised controlled trials

Polydeoxyribonucleotides (PDRNs) From Skin to Musculoskeletal Tissue Regeneration via Adenosine A_2A Receptor Involvement

Contact Info

Product

Resources

About

Effectiveness of polydeoxyribonucleotide injection versus normal saline injection for treatment of chronic plantar fasciitis: a prospective randomised clinical trial

Abstract: PDRN injection is an effective and safe treatment option and may be considered for plantar fasciitis.

Cited by 47 publications

References 28 publications

Pharmacological Activity and Clinical Use of PDRN

Pharmacological Activity and Clinical Use of PDRN

Injection therapies for plantar fasciopathy (‘plantar fasciitis’): a systematic review and network meta-analysis of 22 randomised controlled trials

Polydeoxyribonucleotides (PDRNs) From Skin to Musculoskeletal Tissue Regeneration via Adenosine A2A Receptor Involvement

Contact Info

Product

Resources

About

Polydeoxyribonucleotides (PDRNs) From Skin to Musculoskeletal Tissue Regeneration via Adenosine A_2A Receptor Involvement